GPRC5D x CD3

Assets acting on this target.

Class
Bispecific antibody (T-cell engager)
Pathway
T-cell redirection — cross-links GPRC5D on myeloma cells with CD3 on T cells to trigger T-cell-mediated cytotoxicity

GPRC5D is an orphan cell-surface receptor belonging to the G-protein-coupled receptor family. Its expression is largely restricted to malignant plasma cells in multiple myeloma and to keratinized tissues such as hair follicles and, to some extent, skin and nail structures, with minimal presence on other normal cell types. This restricted distribution makes it an attractive target for redirecting immune attack against myeloma cells while limiting exposure elsewhere in the body. A GPRC5D x CD3 bispecific antibody is engineered to bind simultaneously to GPRC5D on tumor cells and to CD3, a component of the T-cell receptor complex on cytotoxic T lymphocytes. This dual binding physically bridges a T cell to a tumor cell, forming an artificial immunological synapse that activates the T cell independently of its native antigen-recognition machinery. Activated T cells then release cytotoxic granules containing perforin and granzymes, killing the myeloma cell directly. This approach broadens the immunotherapeutic toolkit for multiple myeloma beyond BCMA-directed agents, offering an alternative or complementary antigen target that may remain effective if BCMA expression is lost or downregulated during disease progression.

By indication

Related mechanisms

GPRC5D x CD3 drugs compared

4 drugs, stage by indication
4 drugs acting on GPRC5D x CD3: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
TalquetamabJohnson & Johnsonbispecific antibody (T-cell engager)ApprovedApproved in Multiple Myeloma
QLS32015Qilu Pharmaceuticalbispecific antibodyPhase 3Phase 3 in Multiple Myeloma
LBL-034Nanjing Leads Biolabs Co.,Ltdbispecific antibodyPhase 1/2Phase 1/2 in Multiple Myeloma
TQB2029Sino Biopharmaceuticalbispecific antibody (T-cell engager)Phase 1Phase 1 in Multiple Myeloma

← all mechanisms